koselugohcp.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Disallow: | ||
Meta Tags
| Title | NF1 PN Treatment for Pediatric Patients | KOSELUGO® (selumetinib) 10 mg & 25 mg capsules | For |
| Description | IMPORTANT SAFETY Learn about KOSELUGO® (selumetinib), a treatment for neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients 2 years of age and |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 13.32.121.45 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
koselugohcp.com Valuation
|
US$2,109,635
Last updated: 2023-05-18 15:16:54
koselugohcp.com has Semrush global rank of 5,017,126. koselugohcp.com has an estimated worth of US$ 2,109,635, based on its estimated Ads revenue. koselugohcp.com receives approximately 243,420 unique visitors each day. Its web server is located in United States, with IP address 13.32.121.45. According to SiteAdvisor, koselugohcp.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$2,109,635 |
| Daily Ads Revenue | US$1,948 |
| Monthly Ads Revenue | US$58,421 |
| Yearly Ads Revenue | US$701,048 |
| Daily Unique Visitors | 16,228 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| koselugohcp.com. | A | 295 | IP: 13.32.121.45 |
| koselugohcp.com. | A | 295 | IP: 13.32.121.73 |
| koselugohcp.com. | A | 295 | IP: 13.32.121.14 |
| koselugohcp.com. | A | 295 | IP: 13.32.121.53 |
| koselugohcp.com. | NS | 21600 | NS Record: ns-1211.awsdns-23.org. |
| koselugohcp.com. | NS | 21600 | NS Record: ns-1605.awsdns-08.co.uk. |
| koselugohcp.com. | NS | 21600 | NS Record: ns-193.awsdns-24.com. |
| koselugohcp.com. | NS | 21600 | NS Record: ns-756.awsdns-30.net. |
HtmlToTextCheckTime:2023-05-18 15:16:54
| Important Safety Information Prescribing Information Important Safety Information Prescribing Information Patient Website OneSource TM --> Navigation Impact of PN IMPACT OF PN Natural History Study MOA & Study Design Sprint Study Design MOD/MOA Efficacy Primary Efficacy Results Response Over Time Exploratory Endpoint Safety Profile Dosing Treatment Journey Dosing and Administration OneSource™ Resources Downloads Videos Registration Successful... null you have successfully logged registered and logged in KOSELUGO® (selumetinib), the FIRST and ONLY FDA-approved treatment for pediatric patients 2 years of age and older who have neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN) 1 Koselugo is proven to shrink NF1 PN, and most patients who responded had a duration of response ≥12 months.* 1 *66% of patients achieved objective response (defined as ≥20% reduction of the HCP-identified target PN) according to an AstraZeneca analysis of National Cancer |
koselugohcp.com Whois Information
Domain Name: KOSELUGOHCP.COM Registry Domain ID: 2441382712_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.corporatedomains.com Registrar URL: http://cscdbs.com Updated Date: 2022-06-24T13:49:48Z Creation Date: 2019-10-08T14:58:42Z Registry Expiry Date: 2022-10-08T14:58:42Z Registrar: CSC Corporate Domains, Inc. Registrar IANA ID: 299 Registrar Abuse Contact Email: domainabuse@cscglobal.com Registrar Abuse Contact Phone: 8887802723 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS-1211.AWSDNS-23.ORG Name Server: NS-1605.AWSDNS-08.CO.UK Name Server: NS-193.AWSDNS-24.COM Name Server: NS-756.AWSDNS-30.NET DNSSEC: unsigned >>> Last update of whois database: 2022-06-29T08:44:58Z <<< |